160 related articles for article (PubMed ID: 23918833)
1. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.
Mirzoeva OK; Collisson EA; Schaefer PM; Hann B; Hom YK; Ko AH; Korn WM
Mol Cancer Ther; 2013 Oct; 12(10):2213-25. PubMed ID: 23918833
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
3. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.
Yang Y; Ahn YH; Chen Y; Tan X; Guo L; Gibbons DL; Ungewiss C; Peng DH; Liu X; Lin SH; Thilaganathan N; Wistuba II; Rodriguez-Canales J; McLendon G; Creighton CJ; Kurie JM
J Clin Invest; 2014 Jun; 124(6):2696-708. PubMed ID: 24762440
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
Ji Z; Mei FC; Xie J; Cheng X
J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
Hamidi H; Lu M; Chau K; Anderson L; Fejzo M; Ginther C; Linnartz R; Zubel A; Slamon DJ; Finn RS
Br J Cancer; 2014 Oct; 111(9):1788-801. PubMed ID: 25167228
[TBL] [Abstract][Full Text] [Related]
7. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
8. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
[TBL] [Abstract][Full Text] [Related]
9. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism.
Sureban SM; May R; Lightfoot SA; Hoskins AB; Lerner M; Brackett DJ; Postier RG; Ramanujam R; Mohammed A; Rao CV; Wyche JH; Anant S; Houchen CW
Cancer Res; 2011 Mar; 71(6):2328-38. PubMed ID: 21285251
[TBL] [Abstract][Full Text] [Related]
10. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer.
Stinson S; Lackner MR; Adai AT; Yu N; Kim HJ; O'Brien C; Spoerke J; Jhunjhunwala S; Boyd Z; Januario T; Newman RJ; Yue P; Bourgon R; Modrusan Z; Stern HM; Warming S; de Sauvage FJ; Amler L; Yeh RF; Dornan D
Sci Signal; 2011 Jun; 4(177):ra41. PubMed ID: 21673316
[TBL] [Abstract][Full Text] [Related]
11. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Peng DH; Kundu ST; Fradette JJ; Diao L; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Mino B; Yang Y; Minelli R; Peoples MD; Bristow CA; Heffernan TP; Carugo A; Wistuba II; Gibbons DL
Sci Transl Med; 2019 Mar; 11(483):. PubMed ID: 30867319
[TBL] [Abstract][Full Text] [Related]
12. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
13. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
14. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
15. Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells.
Wang F; Sloss C; Zhang X; Lee SW; Cusack JC
Cancer Res; 2007 Sep; 67(18):8486-93. PubMed ID: 17875687
[TBL] [Abstract][Full Text] [Related]
16. Zeb1 in Stromal Myofibroblasts Promotes
Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
[TBL] [Abstract][Full Text] [Related]
17. Mutant KRAS is a druggable target for pancreatic cancer.
Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
[TBL] [Abstract][Full Text] [Related]
18. EGF receptor is required for KRAS-induced pancreatic tumorigenesis.
Ardito CM; Grüner BM; Takeuchi KK; Lubeseder-Martellato C; Teichmann N; Mazur PK; Delgiorno KE; Carpenter ES; Halbrook CJ; Hall JC; Pal D; Briel T; Herner A; Trajkovic-Arsic M; Sipos B; Liou GY; Storz P; Murray NR; Threadgill DW; Sibilia M; Washington MK; Wilson CL; Schmid RM; Raines EW; Crawford HC; Siveke JT
Cancer Cell; 2012 Sep; 22(3):304-17. PubMed ID: 22975374
[TBL] [Abstract][Full Text] [Related]
19. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.
Collisson EA; Trejo CL; Silva JM; Gu S; Korkola JE; Heiser LM; Charles RP; Rabinovich BA; Hann B; Dankort D; Spellman PT; Phillips WA; Gray JW; McMahon M
Cancer Discov; 2012 Aug; 2(8):685-93. PubMed ID: 22628411
[TBL] [Abstract][Full Text] [Related]
20. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
